Autopsy report · NCT05265013

ASP-1929 Photoimmunotherapy Combined With Pembrolizumab in Patients With Recurrent Head and Neck Cancer, With or Without Metastases

Cause of deathFunding or business Automatic label, confidence 0.9, unverified. How labels are made.

“Business decision”

The sponsor’s own words in the registry.

Life of this trial

Registered 3 months before it started.
Ran for about 1 year 11 months before it stopped.
16 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 2
Sponsor: Rakuten Medical, Inc.
Sponsor type: Industry
Conditions: Head and Neck Cancer
Interventions: ASP-1929 Photoimmunotherapy; pembrolizumab
Participants: 16
Sites: 5
Countries: Taiwan

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.